Aly-Khan Lalani

19PUBLICATIONS
135CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series Analysis.

|Mar 27, 2026
Outcomes and Predictors of Recurrence and Survival in Surgically Resected Localized Chromophobe Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis).

Erica Arenovich, Rodney Breau, Ricardo Rendon

|Jan 13, 2026
Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada.

David-Dan Nguyen, Raj Satkunasivam, Khatereh Aminoltejari

|Feb 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients.

Noa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh

|Nov 08, 2024
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Eric Winquist, Sebastien J Hotte, Kim Chi

Pageof 4

Frequent Collaborators

4 joint publications

Frederic Pouliot

3 joint publications

Lori Wood

3 joint publications

Toni K Choueiri

3 joint publications

Dominick Bossé